Plainsboro, New Jersey, USA, and Bagsværd, Denmark, November 15, 2026
Novo Nordisk has announced two new post hoc analyses from its Phase 3 REDEFINE 1 clinical trial, providing additional insights into the weight-loss response and quality-of-life benefits associated with its investigational obesity treatment CagriSema. The findings were presented at ObesityWeek 2026 in Washington, D.C., and examined how patients respond to treatment during the initial weeks, as well as changes in physical and psychosocial functioning over 68 weeks. CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. In the early-response analysis, 67.8% of participants receiving CagriSema achieved at least 5% body-weight reduction within the first eight weeks of treatment. These early responders experienced an observed average weight reduction of 25.4% at Week 68, compared with 17.8% among participants classified as delayed responders. A separate analysis also demonstrated improvements in patient-reported physical and psychosocial functioning compared with placebo. The findings provide additional evidence about the potential effects of combination-based obesity treatment beyond numerical weight reduction.
REDEFINE 1 Analysis Highlights Early Weight-Loss Response
The first post hoc analysis evaluated individual weight-loss patterns among adults with overweight or obesity who received CagriSema 2.4 mg/2.4 mg in the Phase 3 REDEFINE 1 study. Participants were classified according to their weight reduction during the first eight weeks of treatment. Those achieving at least 5% weight loss were categorised as early responders, while participants achieving less than 5% were classified as delayed responders. Among the CagriSema-treated participants included in the analysis, 1,367 were early responders and 649 were delayed responders. Early responders achieved an average weight reduction of 7.8% at Week 8, compared with 3.4% among delayed responders. By Week 68, the observed average weight reduction reached 25.4% among early responders and 17.8% among delayed responders. Furthermore, 73.3% of early responders achieved at least 20% weight loss, compared with 37.2% of delayed responders. The analysis also found that women were more likely to be early responders than delayed responders, with respective proportions of 71.8% and 59.5%. These findings demonstrate that individuals may experience different weight-loss trajectories even when receiving the same investigational treatment. However, Novo Nordisk emphasised that the analysis was post hoc and hypothesis-generating, meaning the findings should not independently determine treatment decisions or predict individual patient outcomes.
CagriSema Shows Improvements in Physical and Psychosocial Function
The second post hoc analysis investigated the impact of CagriSema on participants’ physical and psychosocial functioning using the validated Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) questionnaire. The assessment examined how changes in body weight affected everyday physical activities, mobility, self-esteem and comfort in social situations. At Week 68, 73.1% of participants receiving CagriSema reported a meaningful improvement in physical function, compared with 49.1% receiving placebo. Improvements were also observed in psychosocial functioning, with 69.0% of CagriSema-treated participants reporting meaningful changes compared with 42.1% in the placebo group. The analysis further demonstrated improvements in physical functioning from Week 8 through Week 68. These results suggest that the potential benefits of obesity treatment may extend beyond weight reduction to include improvements in everyday activities and social well-being. The researchers highlighted the importance of assessing obesity treatment outcomes through patient-reported measures because the condition can affect multiple aspects of daily life. The findings provide additional clinical information about the potential impact of CagriSema on quality of life, although they remain exploratory post hoc results rather than a separate primary clinical endpoint.
Safety Profile and Future Regulatory Development
CagriSema’s safety findings in REDEFINE 1 were consistent with the established safety profile observed in previous clinical investigations. The most frequently reported adverse events were gastrointestinal reactions, including nausea, constipation and vomiting, which were generally mild to moderate in severity and mostly transient. Gastrointestinal adverse events occurred in 79.6% of participants receiving CagriSema, compared with 39.9% receiving placebo. Treatment discontinuation due to adverse events was reported in 5.9% of CagriSema-treated participants and 3.5% of placebo recipients. The original REDEFINE 1 Phase 3 study evaluated 3,417 adults with obesity or overweight and at least one weight-related comorbidity, without type 2 diabetes, over 68 weeks. Novo Nordisk submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration in December 2025 for CagriSema 2.4 mg/2.4 mg for weight management, with a regulatory decision expected in the fourth quarter of 2026. The latest post hoc analyses add further information to the clinical evidence supporting the investigational combination. CagriSema remains investigational and is not approved for use in the United States. The findings highlight Novo Nordisk’s continued commitment to developing innovative obesity treatments that address weight management, physical health and quality of life.
Source: Novo Nordisk press release



